HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report
Open Access
- 18 January 2011
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (1) , 627-632
Abstract
Neoplasms of the ovary present an increasing challenge to the physician. Neoplastic ovarian cysts can resemble endometriomas in ultrasound imaging and need to be carefully considered in the differential diagnosis. We report the case of a woman with a strong family history of hereditary breast and ovarian cancer, who presented with a pelvic mass. The young girl refused oncogenetic counseling and genetic testing, even though she had a 50% a priori probability of being a BRCA1 mutation carrier. Pelvic magnetic resonance imaging (MRI) and a comparative analysis of the serum concentration of HE-4 and CA125 biomarkers provided accuracy and sensitivity in the diagnosis of a benign ovarian pathology. Based on this experience, we propose that the sensitivity of a screening program based on a HE4 and CA125 assay and MRI in high risk patients with mutations in the BRCA1 and BRCA2 genes may be considered a useful pre-operative tool for the differential diagnosis of pelvic masses.Keywords
This publication has 12 references indexed in Scilit:
- Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young womenTumor Biology, 2010
- HE4: a new potential early biomarker for the recurrence of ovarian cancerTumor Biology, 2010
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control StudyJNCI: Journal of the National Cancer Institute, 2010
- Hereditary ovarian cancerCritical Reviews in Oncology/Hematology, 2009
- Magnetic resonance evaluation of adnexal massesActa Radiologica, 2008
- SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other2008
- BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriersCritical Reviews in Oncology/Hematology, 2006
- The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoformsOncogene, 2002
- Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.1999
- Molecular characterization of epididymal proteinsReviews of Reproduction, 1998